The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

Table 3 Tumor response at 6 months in the two treatment groups

Tumor response	Sorafenib group (n = 40)	TACE + sorafenib group (n = 48)	P
CR, n (%)	2 (5.00%)	3 (6.25%)	1.000
PR, n (%)	3 (7.50%)	6 (12.50%)	0.502
SD, n (%)	18 (45.00%)	18 (37.50%)	0.476
PD, n (%)	17 (42.50%)	21 (43.75%)	0.906
OR, n (%)	5 (12.50%)	9 (18.75%)	0.425

CR complete response, OR overall response (CR + PR), PD progressive disease, PR partial response, SD stable disease

ISSN: 1471-2407